The purpose of this survey was to identify perceived educational needs regarding the management of older patients with glioblastoma multiforme (GBM)

1. Glioblastoma Educational Needs Survey The purpose of this survey was to identify perceived educational needs regarding the management of older patients with glioblastoma multiforme (GBM)

2. Demographics Total Respondents N = 25

3. Demographics How many patients with GBM do you manage per week? What percentage of your patients with GBM are 70 years of age or older? 0 to 3 >4 0 25% to 100% Percent of Respondents

4. Rate the extent to which you agree with each of the following statements: Treatment of patients with recurrent GBM is often a challenge The performance status of my older patients plays a critical role in guiding treatment decisions I know the contraindications to administration of bevacizumab in patients with GBM Mean Response (Strongly disagree, 1; Strongly agree, 5) N = 25

5. How frequently do you: Encourage clinical trial participation for your older GBM patients? Use an aggressive multimodal treatment approach (ie, surgery, radiation, chemotherapy) in a 74-year-old patient with GBM? Assess MGMT methylation in your older patients with GBM? Mean Response (Never, 1; Always, 5) Use concurrent and adjuvant TMZ with RT in your older patients with moderate medical comorbidities and who require assistance in some activities of daily living? N = 25

6. How would you manage a 78-year-old GBM patient with arthritis, adequately controlled diabetes, and whose GBM improved following aggressive surgical resection of the tumor? Short-course of radiation therapy (ie, 2-3 weeks) only None, palliative care Temozolomide only Percent of Respondents Short-course of radiation therapy (ie, 2-3 weeks) + temozolomide Concurrent and adjuvant temozolomide with radiation therapy (ie, Stupp regimen) N = 25

7. Please rate your confidence in each of the following: Differentiation radiographic changes that mimic tumor progression from legitimate radiographic changes in tumor size following treatment Communicating with my older patients about the value of clinical trial participation Identifying clinical trials to enroll my older patients Mean Response (Not at all confident, 1; Extremely confident, 5) Managing older patients Assessing performance status/patient fitness Managing treatment-related side effects Communicating with neurologists, oncologists, radiation oncologists, and neurogsurgeons N = 25